These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 8792396)

  • 21. Recombinant human growth hormone plus recombinant human insulin-like growth factor-1 coadministration therapy in short children with low insulin-like growth factor-1 and growth hormone sufficiency: results from a randomized, multicenter, open-label, parallel-group, active treatment-controlled trial.
    Backeljauw PF; Miller BS; Dutailly P; Houchard A; Lawson E; Hale DE; Reiner B; Sperling MA;
    Horm Res Paediatr; 2015; 83(4):268-79. PubMed ID: 25765099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin-like growth factor-I but not growth hormone attenuates dexamethasone-induced catabolism in parenterally fed rats.
    Lo HC; Hinton PS; Yang H; Unterman TG; Ney DM
    JPEN J Parenter Enteral Nutr; 1996; 20(3):171-7. PubMed ID: 8776688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acid-base homeostasis parallels anabolism in surgically stressed rats treated with GH and IGF-I.
    Evans SJ; Lo HC; Ney DM; Welbourne TC
    Am J Physiol; 1996 Jun; 270(6 Pt 1):E968-74. PubMed ID: 8764180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans.
    Hartman ML; Clayton PE; Johnson ML; Celniker A; Perlman AJ; Alberti KG; Thorner MO
    J Clin Invest; 1993 Jun; 91(6):2453-62. PubMed ID: 8514857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans.
    Clemmons DR; Smith-Banks A; Underwood LE
    J Clin Endocrinol Metab; 1992 Jul; 75(1):234-8. PubMed ID: 1619015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of rhGH and rhIGF-1 on renal growth and morphology.
    Mehls O; Irzynjec T; Ritz E; Eden S; Kovàcs G; Klaus G; Floege J; Mall G
    Kidney Int; 1993 Dec; 44(6):1251-8. PubMed ID: 7905540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L; Maccario M; Lanfranco F; Ramunni J; Di Vito L; Grottoli S; Muller EE; Ghigo E; Arvat E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth hormone or insulin-like growth factor I increases fat oxidation and decreases protein oxidation without altering energy expenditure in parenterally fed rats.
    Lo HC; Hirvonen MD; Kritsch KR; Keesey RE; Ney DM
    Am J Clin Nutr; 1997 May; 65(5):1384-90. PubMed ID: 9129466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leptin is suppressed during infusion of recombinant human insulin-like growth factor I (rhIGF I) in normal rats.
    Böni-Schnetzler M; Hauri C; Zapf J
    Diabetologia; 1999 Feb; 42(2):160-6. PubMed ID: 10064095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant human insulin-like growth factor I (IGF-I): risks and benefits of normalizing blood IGF-I concentrations.
    Clark RG
    Horm Res; 2004; 62 Suppl 1():93-100. PubMed ID: 15761240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism.
    Nakae J; Kato M; Murashita M; Shinohara N; Tajima T; Fujieda K
    J Clin Endocrinol Metab; 1998 Feb; 83(2):542-9. PubMed ID: 9467572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous treatment with IGF-I and GH additively increases anabolism in parenterally fed rats.
    Lo HC; Hinton PS; Peterson CA; Ney DM
    Am J Physiol; 1995 Aug; 269(2 Pt 1):E368-76. PubMed ID: 7653554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A rationale for the treatment of short stature in children with the combination of recombinant human growth hormone (rhGH) and recombinant human insulin-like growth factor-I (rhIGF-I).
    Bright GM; Fierro-Renoy JF
    Growth Horm IGF Res; 2020 Jun; 52():101318. PubMed ID: 32252003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women.
    Thompson JL; Butterfield GE; Marcus R; Hintz RL; Van Loan M; Ghiron L; Hoffman AR
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1845-52. PubMed ID: 7539817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency.
    Guevara-Aguirre J; Vasconez O; Martinez V; Martinez AL; Rosenbloom AL; Diamond FB; Gargosky SE; Nonoshita L; Rosenfeld RG
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1393-8. PubMed ID: 7536209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of growth hormone and insulin-like growth factor I in catabolism that is induced by negative energy balance.
    Clemmons DR
    Horm Res; 1993; 40(1-3):62-7. PubMed ID: 8300052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of recombinant human growth hormone and insulin-like growth factor-I, with or without 17 beta-estradiol, on bone and mineral homeostasis of aged ovariectomized rats.
    Verhaeghe J; van Bree R; Van Herck E; Thomas H; Skottner A; Dequeker J; Mosekilde L; Einhorn TA; Bouillon R
    J Bone Miner Res; 1996 Nov; 11(11):1723-35. PubMed ID: 8915780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.